Friday, October 16, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleCrunchbase News

Dell Technologies Capital: How To Build A Deep-Tech Startup For A Market That Isn’t Ready Yet And Why AI Won’t Kill SaaS

View original at news.crunchbase.com

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Dell Technologies Capital did not time the market for its 2025 exits; it stays focused on backing technically strong founders and lets the market catch up over time.

    60% confidence
  • First-mover advantage matters in category disruption but not necessarily in category creation, where later entrants can piggyback on the first mover's market education efforts.

    60% confidence
  • SaaS companies unable to transform organically will need to undergo inorganic transformation via acquisitions over the next 6-24 months to gain AI capability and distribution.

    60% confidence
  • Invest in what you know.

    60% confidence
  • Founders should ask every investor on their cap table for help, regardless of investor type, because 'you don't get what you don't ask for.'

    60% confidence
  • The biggest question when evaluating a Series A or B AI investment today is whether the startup's revenue is durable, given a shift from recurring, multiyear-contract revenue to project-based 're-occuring' revenue.

    60% confidence
  • Play nice but win.

    60% confidence
  • Not all SaaS companies will die from AI disruption; those with smart, effective management that adopt and embrace AI will survive and remain category winners.

    60% confidence
  • The winners among AI startups will almost certainly be the ones who figure out distribution first, best, or fastest.

    60% confidence
  • AI is disruptive to the SaaS world; it will change how software is built, consumed, and priced, with per-seat pricing likely being replaced by consumption- or outcome-based pricing.

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com